Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

People with obesity and prediabetes assigned tirzepatide were more likely to have sustained weight loss than those assigned placebo. Most people on tirzepatide sustained weight loss through 176 weeks.

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

In SAT, 0602K and tirzepatide each produced marked decreases in adipocyte (fat cell) size, with the combination decreasing adipocyte size dramatically more than either alone.

Who cannot take tirzepatide? Mounjaro is not recommended for those who are pregnant or planning to get pregnant, breastfeeding or have certain health conditions, according to the NHS.

Jenny Mollen opened up about how microdosing GLP1 medication ended up sending her to the emergency room. “I just posted a follow-up to my piece about Tirzepatide and microdosing,” Mollen, 46 ...

One comes mixed with tirzepatide, the active ingredient in Eli Lilly's Zepbound ... including those described as "research use only." "We will continue to take action to stop those who threaten ...

A mass rollout of weight loss injections begins across the NHS on Monday, with GPs able to prescribe Mounjaro for the first time. The drug, also known as tirzepatide and manufactured by Lilly, is ...

By Hugo Francisco de Souza A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ...

Last year she bought a compounding pharmacy's version of tirzepatide, paying about $470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs.

Learn about Zepbound (tirzepatide) storage requirements, including how long you can keep Zepbound in the refrigerator, safe disposal of the drug, and more.

In December, GLP-1 agonist tirzepatide (Zepbound) became the first drug approved to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity after two trials showed it reduced ...